I should add, Howard, that the cautious line would be to view SK's backing of the second generation anti-body as only marginally meaningful.
I only say this because, at one time, SK backed the failed CE9.1 version as well. If something goes wrong with this one, they'll dump it too.
Also, the decision to go onto phase II, while good news, doesn't make it any different than it's predecessor either.
I don't mean to be a drag at all. I've been in this stock for years. It's just that, what we have here at most, is another crack at the RA market. It's nice to get that chance but, so far, the trail looks just like CE9.1 which, as far as I know, showed only transient, if any, CD4 depletion in earlier trials. It wasn't until later that such problems showed up with sufficient severity to justify scuttling the trials. The very same course could occur here... then again, maybe not.
BENNETT |
